Comprehensive Income (Loss), Net of Tax, Attributable to Parent of Lexaria Bioscience Corp. from 31 Oct 2010 to 30 Nov 2025

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
Lexaria Bioscience Corp. quarterly and annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD history and change rate from 31 Oct 2010 to 30 Nov 2025.
  • Lexaria Bioscience Corp. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending 30 Nov 2025 was $1,600,751, a 41% increase year-over-year.
  • Lexaria Bioscience Corp. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending 30 Nov 2025 was $10,846,237, a 48% decline year-over-year.
  • Lexaria Bioscience Corp. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2025 was $11,952,360, a 106% decline from 2024.
  • Lexaria Bioscience Corp. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2024 was $5,815,161, a 13% increase from 2023.
  • Lexaria Bioscience Corp. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was $6,664,899.
Source SEC data
View on sec.gov
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Change (%)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Change (%)

Lexaria Bioscience Corp. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $10,846,237 $1,600,751 +$1,106,123 +41% 01 Sep 2025 30 Nov 2025 10-Q 13 Jan 2026 2026 Q1
Q3 2025 $11,952,360 $2,685,100 -$502,360 -23% 01 Jun 2025 31 Aug 2025 10-K 28 Nov 2025 2025 FY
Q2 2025 $11,450,000 $3,751,919 -$1,968,986 -110% 01 Mar 2025 31 May 2025 10-Q 14 Jul 2025 2025 Q3
Q1 2025 $9,481,014 $2,808,467 -$2,133,930 -316% 01 Dec 2024 28 Feb 2025 10-Q 14 Apr 2025 2025 Q2
Q4 2024 $7,347,084 $2,706,874 -$1,531,923 -130% 01 Sep 2024 30 Nov 2024 10-Q 13 Jan 2026 2026 Q1
Q3 2024 $5,815,161 $2,182,740 -$943,421 -76% 01 Jun 2024 31 Aug 2024 10-K 28 Nov 2025 2025 FY
Q2 2024 $4,871,740 $1,782,933 +$588,572 +25% 01 Mar 2024 31 May 2024 10-Q 14 Jul 2025 2025 Q3
Q1 2024 $5,460,312 $674,537 +$623,594 +48% 01 Dec 2023 29 Feb 2024 10-Q 14 Apr 2025 2025 Q2
Q4 2023 $6,083,906 $1,174,951 +$580,993 +33% 01 Sep 2023 30 Nov 2023 10-Q 10 Jan 2025 2025 Q1
Q3 2023 $6,664,899 $1,239,319 01 Jun 2023 31 Aug 2023 10-K 26 Nov 2024 2024 FY
Q2 2023 $2,371,505 01 Mar 2023 31 May 2023 10-Q 12 Jul 2024 2024 Q3
Q1 2023 $1,298,131 01 Dec 2022 28 Feb 2023 10-Q 09 Apr 2024 2024 Q2
Q4 2022 $1,755,944 01 Sep 2022 30 Nov 2022 10-Q 12 Jan 2024 2023 Q1
Q2 2018 $3,432,295 -$3,088,209 -898% 01 Mar 2018 31 May 2018 10-Q 13 Jul 2018 2018 Q3
Q2 2017 $344,086 01 Mar 2017 31 May 2017 10-Q 13 Jul 2018 2018 Q3
Q4 2015 $1,803,813 $382,468 -$33,313 -9.5% 01 Sep 2015 30 Nov 2015 10-Q 08 Jan 2016 2016 Q1
Q3 2015 $1,770,500 $451,729 01 Jun 2015 31 Aug 2015 10-Q 13 Jul 2016 2016 Q3
Q2 2015 $511,008 -$73,012 -17% 01 Mar 2015 31 May 2015 10-Q 14 Jul 2015 2015 Q3
Q1 2015 $458,608 -$332,135 -263% 29 Nov 2014 28 Feb 2015 10-Q 14 Apr 2015 2015 Q2
Q4 2014 $349,155 -$247,263 -243% 01 Sep 2014 30 Nov 2014 10-Q 14 Jan 2015 2015 Q1
Q2 2014 $1,009,912 $437,996 -$380,327 -660% 01 Mar 2014 31 May 2014 10-Q 14 Jul 2015 2015 Q3
Q1 2014 $629,585 $126,473 -$78,935 -166% 29 Nov 2013 28 Feb 2014 10-Q 14 Apr 2015 2015 Q2
Q4 2013 $550,650 $101,892 +$10,182 +9.1% 01 Nov 2013 31 Jan 2014 10-Q 12 Mar 2014 2014 Q1
Q3 2013 $560,832 $343,551 -$374,961 -1194% 01 Sep 2013 31 Oct 2013 10-KT 09 Dec 2014 2014 FY
Q2 2013 $185,871 $57,669 -$125,791 -185% 01 May 2013 31 Jul 2013 10-Q 14 Nov 2014 2014 Q3
Q1 2013 $60,080 $47,538 +$184,581 +80% 01 Feb 2013 30 Apr 2013 10-Q 12 Jun 2014 2014 Q2
Q4 2012 $244,661 $112,074 +$6,847 +5.8% 01 Nov 2012 31 Jan 2013 10-Q 12 Mar 2014 2014 Q1
Q3 2012 $251,508 $31,410 01 Aug 2012 31 Oct 2012 10-K 24 Jan 2014 2013 FY
Q2 2012 $68,122 +$321,091 01 May 2012 31 Jul 2012 10-Q 10 Sep 2013 2013 Q3
Q1 2012 $232,119 01 Feb 2012 30 Apr 2012 10-Q 12 Jun 2013 2013 Q2
Q4 2011 $118,921 01 Nov 2011 31 Jan 2012 10-Q 13 Mar 2013 2013 Q1
Q2 2011 $252,969 01 May 2011 31 Jul 2011 10-Q 12 Sep 2012 2012 Q3

Lexaria Bioscience Corp. Annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $11,952,360 -$6,137,199 -106% 01 Sep 2024 31 Aug 2025 10-K 28 Nov 2025 2025 FY
2024 $5,815,161 +$849,738 +13% 01 Sep 2023 31 Aug 2024 10-K 28 Nov 2025 2025 FY
2023 $6,664,899 01 Sep 2022 31 Aug 2023 10-K 26 Nov 2024 2024 FY
2018 $6,623,434 -$4,693,969 -243% 01 Sep 2017 31 Aug 2018 10-K 14 Nov 2018 2018 FY
2017 $1,929,465 -$652,216 -51% 01 Sep 2016 31 Aug 2017 10-K 14 Nov 2018 2018 FY
2016 $1,277,249 +$493,251 +28% 01 Sep 2015 31 Aug 2016 10-K 14 Nov 2018 2018 FY
2015 $1,770,500 01 Sep 2014 31 Aug 2015 10-Q 13 Jul 2016 2016 Q3
2013 $343,551 -$92,043 -37% 01 Nov 2012 31 Oct 2013 10-KT 09 Dec 2014 2014 FY
2012 $251,508 +$286,718 +53% 01 Nov 2011 31 Oct 2012 10-K 24 Jan 2014 2013 FY
2011 $538,226 +$14,236 +2.6% 01 Nov 2010 31 Oct 2011 10-K 29 Jan 2013 2012 FY
2010 $552,462 01 Nov 2009 31 Oct 2010 10-K 30 Jan 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.